Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2024-11-13 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东股份减持计划届满的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the period, and compliance with relevant regulations. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is not a full financial report, earnings release, or management report, nor is it a regulatory filing or proxy solicitation. It is a specific announcement about shareholding changes by a major shareholder.
2024-11-13 Chinese
关于全资子公司获得《药品补充申请批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its wholly-owned subsidiary receiving an official approval notice from the National Medical Products Administration for a supplemental drug application. It details the drug name, specifications, approval number, and regulatory compliance. The document is short (806 characters) and serves as an announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-11-13 Chinese
关于持股5%以上股东权益变动比例达1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding changes in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shareholding percentages, dates of transactions, and compliance with disclosure obligations. There is no financial data, earnings information, or management discussion. The content fits the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds.
2024-11-04 Chinese
关于2024年前三季度计提减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the impairment provisions made for the first three quarters of 2024. It details the reasons, scope, amounts, and accounting basis for the impairment provisions on various asset categories such as accounts receivable, inventory, and other receivables. The document includes tables with specific impairment amounts and explanations of the accounting policies applied. It also contains statements from the board audit committee and supervisory board confirming the reasonableness of the impairment provisions. The document is relatively short (3,588 characters) and is focused on a specific accounting event (impairment provision) rather than a full financial report. It does not contain comprehensive financial statements or a full quarterly report but rather a specific update on impairment provisions. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting estimates and provisions, not a full interim or annual report, nor a simple earnings release or audit report. It is not a report publication announcement since it contains substantive detail on the impairment provisions themselves.
2024-10-30 Chinese
第四届董事会审计委员会2024年第三次会议的审查意见
Audit Report / Information Classification · 95% confidence The document is a review opinion from the Audit Committee of the Board of Directors regarding the company's 2024 third quarter report. It explicitly states that the committee has examined and approved the 2024 third quarter report, confirming its accuracy and compliance with regulations. The document is short (613 characters) and serves as an audit committee opinion on the quarterly report rather than the full quarterly report itself. It does not contain actual financial statements or substantive financial data but is an audit review statement. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to periodic reports, excluding the full report itself. 9M 2024
2024-10-30 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the approval of the company's 2024 third quarter report. It states that the Supervisory Board has reviewed and approved the third quarter report, confirming its compliance and accuracy. However, the actual third quarter report is not included in this document; instead, it references that the full report is published separately on the cninfo website (announcement number 2024-080). The document is short (758 characters) and serves as an official announcement of the Supervisory Board's meeting resolution and approval of the report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement related to regulatory compliance and disclosure, rather than the Interim/Quarterly Report (IR) itself.
2024-10-30 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.